Immatics Biotechnologies GmbH

Immatics N.V.

General information

Immatics Biotechnologies GmbH
Paul-Ehrlich-Straße 15
72076 Tübingen, Baden-Württemberg
Germany

Contact person: Harpreet Singh, CEO
Company main phone: +49 (7071) 53970
Company main fax: +49 (7071) 5397900
Website: https://www.immatics.com

Year founded:	2000
Source of foundation:	Spin-off from university
Name of foundation source:	H.G. Rammensee's laboratory at the University of Tübingen, Germany
No. of employees:	Worldwide: 210

Corporate description / mission:
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The company’s product candidates are adoptive cell therapies and bispecific TCR molecules.

State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2020

Remarks on ownership / listings
In July 2020, Immatics started trading on NASDAQ as a result of a business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA; or “Arya”), a special purpose acquisition, sponsored by Perceptive Advisors.

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Cell therapy
Immunotherapy

Primary therapeutic areas:

Neoplasms / cancer / oncology

Business model:

In-licensing
Out-licensing
R&D

Customer segments:

Large biotech & big pharma
Small biotech

Distribution:

Indirect (independent dealer)

Summary Products / Services / Technologies

Description of products:
ACTengine® IMA203 (PRAME),
ACTallo® IMA30x,
TCER® IMA401 (MAGEA4/8), ect.

Special IP situation:
The XPRESIDENT technology is protected by granted patents and patent applications.

Technology used:
XPRESIDENT™
XCEPTOR®

Financing details

Market cap. / valuation:

USD 516.76M

Collaborations & Clients

Partnering strategy / collaborations:
Amgen
MDACC
MorphoSys
Roche
Genmab